NanoVibronix 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Brian Murphy

최고 경영자

US$542.1k

총 보상

CEO 급여 비율	55.3%
CEO 임기	8.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	8.1yrs
이사회 평균 재임 기간	8.8yrs

최근 관리 업데이트

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Dec 09

Recent updates

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Dec 09

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Oct 19

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

Sep 23

NanoVibronix announces expansion of distribution pact for its ultrasound devices

Dec 11

NanoVibronix secures $6M in equity capital

Dec 02

NanoVibronix reports Q3 results

Nov 17

CEO 보상 분석

Brian Murphy 의 보수는 NanoVibronix 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$3m
Jun 30 2024	n/a	n/a	-US$3m
Mar 31 2024	n/a	n/a	-US$3m
Dec 31 2023	US$542k	US$300k	-US$4m
Sep 30 2023	n/a	n/a	-US$5m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$409k	US$300k	-US$5m
Sep 30 2022	n/a	n/a	-US$6m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$407k	US$231k	-US$14m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$8m
Dec 31 2020	US$365k	US$231k	-US$4m
Sep 30 2020	n/a	n/a	-US$5m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$4m
Dec 31 2019	US$512k	US$231k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$6m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$591k	US$231k	-US$4m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$6m
Dec 31 2017	US$529k	US$189k	-US$6m

보상 대 시장: Brian 의 총 보상 ($USD 542.13K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 652.28K ).

보상과 수익: 회사가 수익성이 없는 동안 Brian 의 보상이 증가했습니다.

CEO

Brian Murphy (67 yo)

8.1yrs

테뉴어

US$542,131

보상

Mr. Brian M. Murphy has been the Chief Executive Officer of NanoVibronix Inc. since October 13, 2016. Mr. Murphy has sales, operations and general management experience in medical devices and medical techn...

리더십 팀

이름	위치	테뉴어	보상	소유권
Brian Murphy	CEO & Director	8.1yrs	US$542.13k	데이터 없음
Stephen Brown	Chief Financial Officer	4.1yrs	US$361.67k	0.0053% $ 130.0
Harold Jacob	Chief Medical Officer & Director	10.7yrs	US$16.54k	0.016% $ 401.7
Amir Rippel	Vice President of Marketing	no data	데이터 없음	데이터 없음
Lindsey Harrison	Vice President of Sales	no data	데이터 없음	데이터 없음

8.1yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 관리: NAOV 의 관리팀은 노련하고 경험 (평균 재직 기간 8.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Brian Murphy	CEO & Director	8.1yrs	US$542.13k	데이터 없음
Harold Jacob	Chief Medical Officer & Director	21.2yrs	US$16.54k	0.016% $ 401.7
Shalom Hirschman	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Thomas Mika	Independent Director	9.6yrs	US$18.70k	0% $ 0
Christopher Fashek	Independent Chairman of the Board	8.1yrs	US$180.52k	0.10% $ 2.4k
Dennis Maki	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Phillip Hanno	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Samuel Pinchas	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Yechezkiel Caine	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Mitchell Schwaber	Member of Medical Advisory Board	no data	데이터 없음	데이터 없음
Aurora Cassirer	Independent Director	2.8yrs	US$16.79k	0.0027% $ 64.9
Michael Ferguson	Independent Director	9.6yrs	US$18.23k	0% $ 0

8.8yrs

평균 재임 기간

71yo

평균 연령

경험이 풍부한 이사회: NAOV 의 이사회는 경험(평균 재직 기간 8.8 년)으로 간주됩니다.

NanoVibronix 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024

Insufficient new directors

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Insufficient new directors

Insufficient new directors

NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022

Recent updates

Third quarter 2024 earnings released: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)

Nasdaq Notifies NanoVibronix Regarding Potential Delisting Due to Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023)

Insufficient new directors

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Regains Nasdaq Compliance

Third quarter 2023 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2022)

NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix, Inc. announced that it expects to receive $5 million in funding

NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.93 loss in 2Q 2022)

NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.81 loss in 1Q 2022)

Full year 2022 earnings released: US$3.84 loss per share (vs US$11.35 loss in FY 2021)

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Nanovibronix, Inc. Announces Interim Results of Clinical Study for UroShield

Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021)

Insufficient new directors

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Insufficient new directors

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Insufficient new directors

Nanovibronix, Inc. Announces FDA 510(K) Submission for Painshield MD Plus

NanoVibronix, Inc. Adds Additional Product to Federal Supply Schedule

NanoVibronix, Inc. announced delayed annual 10-K filing

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

NanoVibronix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology

NanoVibronix, Inc. Announces Positive Interim Results from Independent, Real World Patient Study of its UroShield

Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

Third quarter 2021 earnings released: US$0.25 loss per share (vs US$0.099 loss in 3Q 2020)

NanoVibronix, Inc. Launches New, Transdermal Gel Containing Nano-Cannabidiol for the Treatment of Joint Pain and Reducing Inflammation

NanoVibronix: Portable Ultrasonic Therapeutic Devices

Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.20 loss in 2Q 2020)

NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

Nanovibronix, Inc Announces That the Therapeutic Goods Administration

Nanovibronix Announces Publication of Compelling Study Results for Uroshield in the Journal of Medical & Surgical Urology

NanoVibronix Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix Receives Notice from Nasdaq for Not Complying with Continued Listing Rule

Nanovibronix Announces Expanded Cms Reimbursement Approval for Painshield

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market

NanoVibronix Regains Nasdaq Compliance

NanoVibronix, Inc. Enters into an Amended and Restated Distribution Agreement

NanoVibronix, Inc. Amends and Expands Distribution Agreement for its Painshield and Painshield Plus with Ultra Pain Products, Inc

NanoVibronix announces expansion of distribution pact for its ultrasound devices

NanoVibronix, Inc Announces Independent Study Finds Significant Benefits Provided by UroShield Device

NanoVibronix secures $6M in equity capital

NanoVibronix reports Q3 results

Nanovibronix Expands Offerings with Introduction of Painshield Plus

NanoVibronix, Inc. Announces Executive Changes

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $1.794783 million.

NanoVibronix's UroShield® Receives U.S. Food and Drug Administration Authorization for Entry into the US

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $3.250001 million.

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix, Inc. announced that it has received $0.1 million in funding from Aigh Capital Management, LLC

NanoVibronix, Inc. announced that it has received $0.2 million in funding from Globis Capital Management, LLC

NanoVibronix, Inc. announced delayed 10-Q filing

CEO 보상 분석

CEO